Table 1 The percentage of ovarian cancer tumors in TCGA are shown with a cut-off of log2 tumor/normal ratio in more than 40 % tumors detected by Agilent G4502A microarray chips
From: Identification of therapeutic targets applicable to clinical strategies in ovarian cancer
Gene | Log2 > 0.5 | Gene | Log2 < −0.5 |
|---|---|---|---|
ALPK2 | 54 % | CSNK1G2 | 63 % |
AURKA | 97 % | DDR2 | 80 % |
BUB1B | 96 % | GUCY2F | 97 % |
CDC7 | 89 % | ITK | 50 % |
EPHB1 | 67 % | LRRK2 | 92 % |
GRK6 | 44 % | MGC42105 | 46 % |
KSR2 | 41 % | MKNK2 | 46 % |
MAP3K7 | 45 % | PDGFRB | 49 % |
NEK2 | 97 % | PRKCB | 61 % |
NLK | 59 % | RET | 41 % |
PIK3AP1 | 58 % | TEK | 91 % |
PLK1 | 58 % | ||
RRM1 | 41 % | ||
TLK1 | 42 % |